Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

BDRX

BDRX News

Newswire

18:14

Biodexa shares surge 39.09% after-hours after enrolling first European patients in Phase 3 Serenta trial.

18:11

Biodexa shares surge 50.79% after-hours as first European patients enrolled in pivotal Phase 3 Serenta trial, targeting $7B FAP market.

18:09

Biodexa shares surge 60.32% after-hours after announcing first European patient enrollment in pivotal Phase 3 Serenta FAP trial.

18:09

Biodexa shares surge 43.65% after-hours after enrolling first European patients in pivotal Phase 3 Serenta FAP trial.

18:06

Biodexa shares surge 20.83% after-hours following enrollment of first European patients in pivotal Phase 3 Serenta trial for FAP.

View More

About BDRX

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More